Funny how an unsolicited bid will suddenly alert Wall Street to the value of a strong biotech.
While Onyx Pharmaceuticals (Nasdaq:ONXX) was generally a pretty well-regarded biotech, the news over the weekend that Amgen (Nasdaq:AMNG) had made a bid, and that management was now soliciting higher offers, has sent the shares rocketing up in pre-market trade. Given its solid collection of oncology/hematology assets, it won't be surprising if Onyx draws a crowd to its bargaining table before declaring a winner.

SEE: The Ups And Downs Of Biotechnology
Good Reporting Triggers A New Era
Financial Post's Barry Critchley offered quite the scoop late Friday when he reported seeing a letter wherein Amgen made a formal bid for Onyx in the amount of $8.7 billion or $120/share. Onyx ultimately acknowledged the bid, but declared it insufficient and that the company was now going to begin an active sales process. To that end, it's worth noting that Onyx's press release acknowledging Amgen's bid made it clear that the company has received other indications of interest.
Who Will Step Up?
Onyx has what almost every pharmaceutical company wants today – a collection of oncology/hematology assets that are of good quality, relatively early in their commercial life-cycle, and likely to offer solid growth in the near term. Accordingly, I don't think Onyx management or investors need to worry about a lack of interest in acquiring this company.
Maybe one of the first companies to consider in any auction process is Bayer – the company's OUS partner for Nexavar and Stivarga. I'm skeptical of the potential that Bayer will get involved. Bayer is pretty rigid when it to return on investment and debt targets, and a bid into the $130s or higher would seriously challenge both of those. While Bayer might like to have the other 50% of profits from Nexavar and Stivarga, Bayer has relatively little direct presence (or assets) in the U.S. and would likely need to do further deals to really leverage a new U.S. presence.

SEE: Evaluating Pharmaceutical Companies
Amgen certainly has to be a name high on the list of potential acquirers. Biotech M&A has long been a market where “if at first you don't succeed...” is very relevant – just because Onyx management didn't like the initial bid doesn't mean the door is closed to a higher offer. Of all the companies potentially interested in Onyx, Amgen may be among the most motivated – Amgen is trying to build an oncology franchise and is presently quite weak in terms of growth, and Onyx would help both issues.
Almost any large pharmaceutical company with a presence in oncology and the US could find some use for Onyx. Novartis (NYSE:NVS), Bristol-Myers (NYSE:BMY), Pfizer (NYSE:PFE) could all fit the bill, and I wouldn't rule out AstraZeneca (NYSE:AZN) which, like Amgen, badly needs near-term growth. I'm also surprised there isn't more initial buzz on Roche (Nasdaq:RHHBY), given the company's huge presence in oncology, its need (arguably) to diversify its oncology assets, and its willingness to pay up for assets.
Last, and certainly not least, are some “mid-majors” with solid oncology footing – Celgene (Nasdaq:CELG) and Gilead (Nasdaq:GILD). Both are strong in hematology, which makes me wonder about the extent to which Onyx would really improve the companies' growth profile over the long-term.
How High Will The Bidding Go?
Although I think Onyx is probably worth about $110 to $125 on its own, the company will clearly go for more than that in a public sale process. Not only do strategic buyers have the opportunity to take out SG&A expenses and leverage complimentary R&D assets, but a strategic buyer may also be able to enhance the long-term revenue potential of Onyx's marketed drugs and pipeline. As such, I could see the price going above $140 and still offering some value for the right buyer.
The Bottom Line
If you don't own Onyx already, this news doesn't really create an investment opportunity. On the other hand, traders may find that trying to play the spread between its open on Monday morning and the eventual deal price is worthwhile. If I were an Onyx shareholder, I'd definitely sit tight – it seems highly improbable to me that the company won't get multiple bids, and I think the odds of the company overplaying its hand such that all of the bidders walk away are relatively low.
Disclosure – As of this writing, the author owns shares of Roche.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center